 |
|
|
| |
Oral Weekly Islatravir Plus Lenacapavir in Virologically Suppressed People with HIV-1:
96 Week Outcomes from a Phase 2 Study
|
| |
| |
EACS 2025, The 20th European AIDS Conference, Paris, France, 15-18 October 2025
Amy E. Colson1*, Gordon E. Crofoot2, Peter J. Ruane3, Moti N. Ramgopal4*, Alexandra W. Dretler5, Ronald G. Nahass6, Gary I. Sinclair7, Mezgebe Berhe8, Afsoon Roberts9, Shauna Applin10, Cynthia Brinson11, Fadi Shihadeh12, Shan-Yu Liu12, Sharline Madera12, Hadas Dvory-Sobol12, Melissa A. Shaughnessy13, Cyril Llamoso13, Elizabeth G. Rhee13, Devi SenGupta12, Joseph Eron14
|
| |
|
|
|
|
|
